^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + KSQ-4279 (USP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors
Published date:
10/12/2022
Excerpt:
KSQ-4279 activity was evaluated in multiple PARPi-resistant, BRCA mutant, ovarian orthotopic PDX models generated from patient tumor samples that have relapsed after multiple rounds of chemotherapy and/or PARPi treatment....the combination of KSQ-4279 and Olaparib led to strong and durable anti-tumor efficacy, including the induction of tumor regressions in several models.